A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Head & Neck · 2026
DOI: 10.1002/hed.70313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2026. Verfasst von Mathias Fiedler und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Immune Checkpoint Inhibitors, Squamous Cell Carcinoma of Head and Neck, Neoplasm Recurrence, Local. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Predictive biomarkers for response to PD‐1 blockade in recurrent or metastatic HNSCC remain limited. We investigated whether coordinated expression of multiple inhibitory immune checkpoints defines a clinically relevant biomarker phenotype.
Methods
Clinical and immunohistochemical data from 78 patients with recurrent or metastatic HNSCC treated with nivolumab or pembrolizumab were retrospectively analyzed. Expression of PD‐L1, LAG‐3, TIM‐3, and IDO1 on tumor‐infiltrating immune cells was assessed. A composite immune checkpoint phenotype was defined by concurrent immune‐cell expression of these markers. Associations with treatment response and survival were analyzed.
Results
The composite immune checkpoint phenotype was observed in 10.1% of tumors and was strongly associated with objective response ( p < 0.001), disease control ( p = 0.006), and improved overall, disease‐specific, and progression‐free survival (all p ≤ 0.030). In multivariable analysis, this phenotype independently predicted overall ( p = 0.031) and disease‐specific survival ( p = 0.011).
Conclusion
Coordinated expression of multiple inhibitory immune checkpoints identifies an inflamed tumor microenvironment associated with improved outcomes following PD‐1 blockade in HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Regensburg, Germany.
- Department of Oral and Maxillofacial Surgery, Center for Medical Biotechnology, University Hospital Regensburg, Regensburg, Germany.
- Institute of Pathology, University of Regensburg, Regensburg, Germany.
- Department of Internal Medicine III, Hematology & Internal Oncology, University Hospital Regensburg, Regensburg, Germany.
- Center of Tumor Registry, University of Regensburg, Regensburg, Germany.
ORCID-Profile: Mathias Fiedler, Tobias Ettl
Zitieren
APA
Fiedler, M., Baumann, L., Eichberger, J., Gottsauner, M., Schuderer, J. G., Schulz, D., Meier, J. K., Bauer, R. J., Poeck, H., Grube, M., Gerken, M., Reichert, T. E., Weber, F., & Ettl, T. (2026). A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck. https://doi.org/10.1002/hed.70313
Vancouver
Fiedler M, Baumann L, Eichberger J, Gottsauner M, Schuderer JG, Schulz D, et al. A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Head & Neck. 2026. doi:10.1002/hed.70313
BibTeX
@article{Fiedler2026,
author = {Fiedler, Mathias and Baumann, Lea and Eichberger, Jonas and Gottsauner, Maximilian and Schuderer, Johannes G and Schulz, Daniela and Meier, Johannes K and Bauer, Richard J and Poeck, Hendrik and Grube, Matthias and Gerken, Michael and Reichert, Torsten E and Weber, Florian and Ettl, Tobias},
title = {A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70313}
}
EUVIMED